Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1994 Mar;93(3):1163–1171. doi: 10.1172/JCI117069

Metabolic clearance of recombinant human growth hormone in health and chronic renal failure.

D Haffner 1, F Schaefer 1, J Girard 1, E Ritz 1, O Mehls 1
PMCID: PMC294067  PMID: 8132756

Abstract

Despite the increasing therapeutic use of recombinant human growth hormone (rhGH), its metabolic clearance has not been investigated in detail. To evaluate the kinetics of rhGH as a possible function of GH plasma concentration and glomerular filtration rate (GFR), we investigated the steady state metabolic clearance rate (MCR), disappearance half-life, and apparent volume of distribution of rhGH at low and high physiological as well as supraphysiological plasma GH levels during pharmacological suppression of endogenous GH secretion in human subjects with normal and reduced renal function. GH in plasma and urine was determined by an immunoradiometric assay, and GFR by inulin clearance. In all subjects MCR decreased and plasma half-life increased with increasing plasma GH concentrations (P < 0.001). MCR of rhGH was approximately half in patients with chronic renal failure at each GH level and plasma half-life was increased by 25-50%. Allowing for the linear dependence of MCR on GFR and assuming single-compartment distribution, the estimated renal fraction of total MCR was 25-53 and 4-15% in controls and patients, respectively. Saturation of extrarenal disposal of GH was suggested by an inverse hyperbolic relationship between extrarenal MCR and plasma GH concentrations in all subjects. Fractional GH excretion was up to 1,000-fold higher in patients than in controls. We conclude that MCR of hGH is a function of plasma GH concentrations and GFR. Extrarenal elimination is saturable in the upper physiological range of GH concentrations, whereas renal MCR is independent of plasma GH levels. The kidney handles GH like a microprotein involving glomerular filtration, tubular reabsorption, and urinary excretion.

Full text

PDF

Images in this article

1167Image
on p.1167
1167Image
on p.1167

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baumann G., Abramson E. C. Urinary growth hormone in man: evidence for multiple molecular forms. J Clin Endocrinol Metab. 1983 Feb;56(2):305–311. doi: 10.1210/jcem-56-2-305. [DOI] [PubMed] [Google Scholar]
  2. Baumann G., Amburn K. D., Buchanan T. A. The effect of circulating growth hormone-binding protein on metabolic clearance, distribution, and degradation of human growth hormone. J Clin Endocrinol Metab. 1987 Apr;64(4):657–660. doi: 10.1210/jcem-64-4-657. [DOI] [PubMed] [Google Scholar]
  3. Baumann G., Amburn K., Shaw M. A. The circulating growth hormone (GH)-binding protein complex: a major constituent of plasma GH in man. Endocrinology. 1988 Mar;122(3):976–984. doi: 10.1210/endo-122-3-976. [DOI] [PubMed] [Google Scholar]
  4. Baumann G., Stolar M. W., Amburn K., Barsano C. P., DeVries B. C. A specific growth hormone-binding protein in human plasma: initial characterization. J Clin Endocrinol Metab. 1986 Jan;62(1):134–141. doi: 10.1210/jcem-62-1-134. [DOI] [PubMed] [Google Scholar]
  5. Blum W. F., Ranke M. B., Bierich J. R. A specific radioimmunoassay for insulin-like growth factor II: the interference of IGF binding proteins can be blocked by excess IGF-I. Acta Endocrinol (Copenh) 1988 Jul;118(3):374–380. doi: 10.1530/acta.0.1180374. [DOI] [PubMed] [Google Scholar]
  6. Blum W. F., Ranke M. B., Bierich J. R. Isolation and partial characterization of six somatomedin-like peptides from human plasma Cohn fraction IV. Acta Endocrinol (Copenh) 1986 Feb;111(2):271–284. doi: 10.1530/acta.0.1110271. [DOI] [PubMed] [Google Scholar]
  7. Blum W. F., Ranke M. B., Kietzmann K., Gauggel E., Zeisel H. J., Bierich J. R. A specific radioimmunoassay for the growth hormone (GH)-dependent somatomedin-binding protein: its use for diagnosis of GH deficiency. J Clin Endocrinol Metab. 1990 May;70(5):1292–1298. doi: 10.1210/jcem-70-5-1292. [DOI] [PubMed] [Google Scholar]
  8. Blum W. F., Ranke M. B., Kietzmann K., Tönshoff B., Mehls O. Growth hormone resistance and inhibition of somatomedin activity by excess of insulin-like growth factor binding protein in uraemia. Pediatr Nephrol. 1991 Jul;5(4):539–544. doi: 10.1007/BF01453697. [DOI] [PubMed] [Google Scholar]
  9. Boucher B. J. Disappearance of iodine-131-labelled human growth hormone from the plasma of diabetic, non-diabetic and acromegalic subjects. Nature. 1966 Jun 18;210(5042):1288–1289. doi: 10.1038/2101288a0. [DOI] [PubMed] [Google Scholar]
  10. Bullier-Picard F., Postel-Vinay M. C., Kayser C. In-vivo uptake of human growth hormone in male rat liver. J Endocrinol. 1989 Apr;121(1):19–25. doi: 10.1677/joe.0.1210019. [DOI] [PubMed] [Google Scholar]
  11. Cameron D. P., Burger H. G., Catt K. J., Doig A. Metabolic clearance rate of radioiodinated human growth hormone in man. J Clin Invest. 1969 Sep;48(9):1600–1608. doi: 10.1172/JCI106125. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Cameron D. P., Burger H. G., Catt K. J., Gordon E., Watts J. M. Metabolic clearance of human growth hormone in patients with hepatic and renal failure, and in the isolated perfused pig liver. Metabolism. 1972 Oct;21(10):895–904. doi: 10.1016/0026-0495(72)90024-8. [DOI] [PubMed] [Google Scholar]
  13. Faria A. C., Veldhuis J. D., Thorner M. O., Vance M. L. Half-time of endogenous growth hormone (GH) disappearance in normal man after stimulation of GH secretion by GH-releasing hormone and suppression with somatostatin. J Clin Endocrinol Metab. 1989 Mar;68(3):535–541. doi: 10.1210/jcem-68-3-535. [DOI] [PubMed] [Google Scholar]
  14. Finidori J., Postel-Vinay M. C., Kleinknecht C. Lactogenic and somatotropic binding sites in liver membranes of rats with renal insufficiency. Endocrinology. 1980 Jun;106(6):1960–1965. doi: 10.1210/endo-106-6-1960. [DOI] [PubMed] [Google Scholar]
  15. Girard J., Erb T., Pampalone A., Eberle A. N., Baumann J. B. Growth hormone in urine: development of an ultrasensitive assay applicable to plasma and urine. Horm Res. 1987;28(1):71–80. doi: 10.1159/000180928. [DOI] [PubMed] [Google Scholar]
  16. Haffner D., Zacharewicz S., Mehls O., Heinrich U., Ritz E. The acute effect of growth hormone on GFR is obliterated in chronic renal failure. Clin Nephrol. 1989 Dec;32(6):266–269. [PubMed] [Google Scholar]
  17. Harrison J. F., Lunt G. S., Scott P., Blainey J. D. Urinary lysozyme, ribonuclease, and low-molecular-weight protein in renal disease. Lancet. 1968 Feb 24;1(7539):371–375. doi: 10.1016/s0140-6736(68)91350-0. [DOI] [PubMed] [Google Scholar]
  18. Hattori N., Kato Y., Murakami Y., Hashida S., Ishikawa E., Mohri Z., Imura H. Urinary growth hormone levels measured by ultrasensitive enzyme immunoassay in patients with renal insufficiency. J Clin Endocrinol Metab. 1988 Apr;66(4):727–732. doi: 10.1210/jcem-66-4-727. [DOI] [PubMed] [Google Scholar]
  19. Hattori N., Shimatsu A., Kato Y., Imura H. Growth hormone and growth hormone binding protein in human urine. Kidney Int. 1990 Mar;37(3):951–954. doi: 10.1038/ki.1990.70. [DOI] [PubMed] [Google Scholar]
  20. Hendricks C. M., Eastman R. C., Takeda S., Asakawa K., Gorden P. Plasma clearance of intravenously administered pituitary human growth hormone: gel filtration studies of heterogeneous components. J Clin Endocrinol Metab. 1985 May;60(5):864–867. doi: 10.1210/jcem-60-5-864. [DOI] [PubMed] [Google Scholar]
  21. Herington A. C., Ymer S., Stevenson J. Identification and characterization of specific binding proteins for growth hormone in normal human sera. J Clin Invest. 1986 Jun;77(6):1817–1823. doi: 10.1172/JCI112507. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Hokken-Koelega A. C., Hackeng W. H., Stijnen T., Wit J. M., de Muinck Keizer-Schrama S. M., Drop S. L. Twenty-four-hour plasma growth hormone (GH) profiles, urinary GH excretion, and plasma insulin-like growth factor-I and -II levels in prepubertal children with chronic renal insufficiency and severe growth retardation. J Clin Endocrinol Metab. 1990 Sep;71(3):688–695. doi: 10.1210/jcem-71-3-688. [DOI] [PubMed] [Google Scholar]
  23. Hruska K. A., Korkor A., Martin K., Slatopolsky E. Peripheral metabolism of intact parathyroid hormone. Role of liver and kidney and the effect of chronic renal failure. J Clin Invest. 1981 Mar;67(3):885–892. doi: 10.1172/JCI110106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Husman B., Gustafsson J. A., Andersson G. Receptor-mediated endocytosis and degradation of bovine growth hormone in rat liver. Mol Cell Endocrinol. 1988 Sep;59(1-2):13–25. doi: 10.1016/0303-7207(88)90191-8. [DOI] [PubMed] [Google Scholar]
  25. Johnson V., Maack T. Renal extraction, filtration, absorption, and catabolism of growth hormone. Am J Physiol. 1977 Sep;233(3):F185–F196. doi: 10.1152/ajprenal.1977.233.3.F185. [DOI] [PubMed] [Google Scholar]
  26. Koch V. H., Lippe B. M., Nelson P. A., Boechat M. I., Sherman B. M., Fine R. N. Accelerated growth after recombinant human growth hormone treatment of children with chronic renal failure. J Pediatr. 1989 Sep;115(3):365–371. doi: 10.1016/s0022-3476(89)80833-9. [DOI] [PubMed] [Google Scholar]
  27. Kowarski A., Thompson R. G., Migeon C. J., Blizzard R. M. Determination of integrated plasma concentrations and true secretion rates of human growth hormone. J Clin Endocrinol Metab. 1971 Mar;32(3):356–360. doi: 10.1210/jcem-32-3-356. [DOI] [PubMed] [Google Scholar]
  28. Lee P. D., Hintz R. L., Sperry J. B., Baxter R. C., Powell D. R. IGF binding proteins in growth-retarded children with chronic renal failure. Pediatr Res. 1989 Oct;26(4):308–315. doi: 10.1203/00006450-198910000-00005. [DOI] [PubMed] [Google Scholar]
  29. MacGillivray M. H., Frohman L. A., Doe J. Metabolic clearance and production rates of human growth hormone in subjects with normal and abnormal growth. J Clin Endocrinol Metab. 1970 May;30(5):632–638. doi: 10.1210/jcem-30-5-632. [DOI] [PubMed] [Google Scholar]
  30. Martha P. M., Jr, Gorman K. M., Blizzard R. M., Rogol A. D., Veldhuis J. D. Endogenous growth hormone secretion and clearance rates in normal boys, as determined by deconvolution analysis: relationship to age, pubertal status, and body mass. J Clin Endocrinol Metab. 1992 Feb;74(2):336–344. doi: 10.1210/jcem.74.2.1730812. [DOI] [PubMed] [Google Scholar]
  31. Owens D., Srivastava M. C., Tompkins C. V., Nabarro J. D., Sönksen P. H. Studies on the metabolic clearance rate, apparent distribution space and plasma half-disappearance time of unlabelled human growth hormone in normal subjects and in patients with liver disease, renal disease, thyroid disease and diabetes mellitus. Eur J Clin Invest. 1973 Jul;3(4):284–294. doi: 10.1111/j.1365-2362.1973.tb00353.x. [DOI] [PubMed] [Google Scholar]
  32. PARKER M. L., UTIGER R. D., DAUGHADAY W. H. Studies on human growth hormone. II. The physiological disposition and metabolic fate of human growth hormone in man. J Clin Invest. 1962 Feb;41:262–268. doi: 10.1172/JCI104479. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Pimstone B. L., Le Roith D., Epstein S., Kronheim S. Disappearance rates of plasma growth hormone after intravenous somatostatin in renal and liver disease. J Clin Endocrinol Metab. 1975 Aug;41(2):392–393. doi: 10.1210/jcem-41-2-392. [DOI] [PubMed] [Google Scholar]
  34. Rabkin R., Gottheiner T. I., Fang V. S. Removal and excretion of immunoreactive rat growth hormone by the isolated kidney. Am J Physiol. 1981 Apr;240(4):F282–F287. doi: 10.1152/ajprenal.1981.240.4.F282. [DOI] [PubMed] [Google Scholar]
  35. Ramirez G., O'Neill W. M., Bloomer H. A., Jubiz W. Abnormalities in the regulation of growth hormone in chronic renal failure. Arch Intern Med. 1978 Feb;138(2):267–271. [PubMed] [Google Scholar]
  36. Refetoff S., Sönksen P. H. Disappearance rate of endogenous and exogenous human growth hormone in man. J Clin Endocrinol Metab. 1970 Mar;30(3):386–392. doi: 10.1210/jcem-30-3-386. [DOI] [PubMed] [Google Scholar]
  37. Ritz E., Tönshoff B., Worgall S., Kovacs G., Mehls O. Influence of growth hormone and insulin-like growth factor-I on kidney function and kidney growth. Pediatr Nephrol. 1991 Jul;5(4):509–512. doi: 10.1007/BF01453692. [DOI] [PubMed] [Google Scholar]
  38. Rosenbaum M., Gertner J. M. Metabolic clearance rates of synthetic human growth hormone in children, adult women, and adult men. J Clin Endocrinol Metab. 1989 Oct;69(4):820–824. doi: 10.1210/jcem-69-4-821. [DOI] [PubMed] [Google Scholar]
  39. Samaan N. A., Freeman R. M. Growth hormone levels in severe renal failure. Metabolism. 1970 Feb;19(2):102–113. [PubMed] [Google Scholar]
  40. Schaefer F., Hamill G., Stanhope R., Preece M. A., Schärer K. Pulsatile growth hormone secretion in peripubertal patients with chronic renal failure. Cooperative Study Group on Pubertal Development in Chronic Renal Failure. J Pediatr. 1991 Oct;119(4):568–577. doi: 10.1016/s0022-3476(05)82406-0. [DOI] [PubMed] [Google Scholar]
  41. Sherman R. L., Drayer D. E., Leyland-Jones B. R., Reidenberg M. M. N-acetyl-beta-glucosaminidase and beta 2-microglobulin. Their urinary excretion in patients with renal parenchymal disease. Arch Intern Med. 1983 Jun;143(6):1183–1185. doi: 10.1001/archinte.143.6.1183. [DOI] [PubMed] [Google Scholar]
  42. Skorecki K. L., Brenner B. M. Body fluid homeostasis in man. A contemporary overview. Am J Med. 1981 Jan;70(1):77–88. doi: 10.1016/0002-9343(81)90414-9. [DOI] [PubMed] [Google Scholar]
  43. TAIT J. F. REVIEW: THE USE OF ISOTOPIC STEROIDS FOR THE MEASUREMENT OF PRODUCTION RATES IN VIVO. J Clin Endocrinol Metab. 1963 Dec;23:1285–1297. doi: 10.1210/jcem-23-12-1285. [DOI] [PubMed] [Google Scholar]
  44. Tar A., Hocquette J. F., Souberbielle J. C., Clot J. P., Brauner R., Postel-Vinay M. C. Evaluation of the growth hormone-binding proteins in human plasma using high pressure liquid chromatography gel filtration. J Clin Endocrinol Metab. 1990 Nov;71(5):1202–1207. doi: 10.1210/jcem-71-5-1202. [DOI] [PubMed] [Google Scholar]
  45. Taylor A. L., Finster J. L., Mintz D. H. Metabolic clearance and production rates of human growth hormone. J Clin Invest. 1969 Dec;48(12):2349–2358. doi: 10.1172/JCI106201. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Tönshoff B., Dietz M., Haffner D., Tönshoff C., Stöver B., Mehls O. Effects of two years of growth hormone treatment in short children with renal disease. The German Study Group for Growth Hormone Treatment in Chronic Renal Failure. Acta Paediatr Scand Suppl. 1991;379:33–41. doi: 10.1111/j.1651-2227.1991.tb12041.x. [DOI] [PubMed] [Google Scholar]
  47. Tönshoff B., Heinrich U., Mehls O. How safe is the treatment of uraemic children with recombinant human growth hormone? Pediatr Nephrol. 1991 Jul;5(4):454–460. doi: 10.1007/BF01453681. [DOI] [PubMed] [Google Scholar]
  48. Tönshoff B., Mehis O., Heinrich U., Blum W. F., Ranke M. B., Schauer A. Growth-stimulating effects of recombinant human growth hormone in children with end-stage renal disease. J Pediatr. 1990 Apr;116(4):561–566. doi: 10.1016/s0022-3476(05)81603-8. [DOI] [PubMed] [Google Scholar]
  49. Veldhuis J. D., Johnson M. L., Faunt L. M., Mercado M., Baumann G. Influence of the high-affinity growth hormone (GH)-binding protein on plasma profiles of free and bound GH and on the apparent half-life of GH. Modeling analysis and clinical applications. J Clin Invest. 1993 Feb;91(2):629–641. doi: 10.1172/JCI116243. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Weissberger A. J., Ho K. Y., Stuart M. C. Quantification of urinary growth hormone (GH) excretion by centrifugal ultrafiltration and radioimmunoassay: appraisal of the relationship between 24 h urinary GH and mean 24 h serum GH levels in normal and abnormal states of GH secretion. Clin Endocrinol (Oxf) 1989 Jun;30(6):687–698. doi: 10.1111/j.1365-2265.1989.tb00275.x. [DOI] [PubMed] [Google Scholar]
  51. ZILVERSMIT D. B. The design and analysis of isotope experiments. Am J Med. 1960 Nov;29:832–848. doi: 10.1016/0002-9343(60)90117-0. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES